Randomized controlled trial reduced MMP-9 and NGAL levels in diabetic patients, indicating P. crocatum's potential benefit.
Context: Diabetic nephropathy (DN) remains a leading cause of end-stage renal disease, largely driven by inflammation and oxidative stress. Piper crocatum is rich in bioactive compounds with antioxidant and anti-inflammatory effects. Aims: To evaluate the effects of P. crocatum-enriched functional foods on renal biomarkers in diabetic patients with early renal dysfunction. Methods: A 12-week double-blind, randomized, placebo-controlled trial was conducted among 387 diabetic adults with mild renal impairment. Participants consumed either P. crocatum-enriched cookies or placebo cookies. Serum matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL), and the MMP-9-NGAL ratio were measured pre- and post-intervention. Results: Compared with placebo, P. crocatum significantly reduced MMP-9 (518.45 to 350.34 ng/mL, false discovery rate (FDR)-adjusted p=0.0003), NGAL (195.67 to 174.31 ng/mL, FDR-adjusted p=0.0016), and the MMP-9-NGAL ratio (2.65 to 1.99, FDR-adjusted p=0.0011). Effect sizes were large. The placebo showed minimal changes. Conclusions: P. crocatum supplementation improved renal inflammation and oxidative stress markers, suggesting its potential as an adjunct therapy for DN.
No takes yet. Share an insight, caveat, or question.
Setyawati et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: